Ascletis Pharma Inc.

Investors

Voluntary Announcement - Gannex Announces Positive Topline Results from the U.S. Phase I Trial of Drug-Drug Interactions in Healthy Subjects and Pharmacokinetics in Patients with NAFLD for Its THRbeta Agonist ASC41
2021-09-08
Voluntary Announcement - Gannex Announces Clinical Trial Application of ASC42, An FXR Agonist, for Treatment of Primary Biliary Cholangitis Accepted by China NMPA
2021-09-06
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 August 2021
2021-09-03
2021 Interim Results Conference Call (Chinese)
2021-08-27
2021 Interim Results
2021-08-26
Voluntary Announcement - Ascletis Announces Completion of the Bridging Study and Initiation of Phase II Trial of FXR Agonist ASC42 in China for Chronic Hepatitis B Indication
2021-08-25
Voluntary Announcement - Ascletis' Partner Sagimet Dosed First Patient in FASCINATE-2 Phase IIb Trial in NASH Patients with Moderate to Advanced Fibrosis
2021-08-16
Notice of Board Meeting
2021-08-13
Voluntary Announcement - China NMPA Approves Phase II Clinical Trial of ASC40 for the Treatment of Patients with Acne
2021-08-09
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 July 2021
2021-08-05

1

© 2018 Ascletis Pharma Inc. All Rights Reserved
浙公网安备 33010802003344号浙ICP备 11050387号